Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
Stock Information for Portage Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.